Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket
$ATXI
$AVCT
$BBIG
$CRHC
Biotechnology: Pharmaceutical Preparations
Health Care
EDP Services
Technology
Gainers
- RedHill Biopharma Ltd. (NASDAQ:RDHL) rose 31.4% to $0.6525 in pre-market trading after dipping over 20% on Friday. The European Commission, last month, granted Orphan Drug Designation to RedHill Biopharma’s lead asset RHB-204 for the treatment of nontuberculous mycobacteria (NTM) disease.
- Smart for Life, Inc. (NASDAQ:SMFL) rose 22.7% to $0.41705 in pre-market trading after dropping around 23% on Friday.
- Gaotu Techedu Inc. (NYSE:GOTU) shares rose 20.7% to $1.40 in pre-market trading. Gaotu Techedu recently reported Q2 sales of $80.29 million.
- American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) rose 15.9% to $0.3920 in pre-market trading after gaining over 8% on Friday.
- Vinco Ventures, Inc. (NASDAQ:BBIG) rose 15.5% to $1.03 in pre-market trading.
- Silver Crest Acquisition Corporation (NASDAQ:SLCR) rose 13.5% to $8.08 in pre-market trading after tumbling over 22% on Friday.
- Tuesday Morning Corporation (NASDAQ:TUEM) rose 13.4% to $0.1588 in pre-market trading. Tuesday Morning, on Friday, posted a Q4 loss of $0.33 per share.
- iSpecimen Inc. (NASDAQ:ISPC) rose 10.6% to $2.30 in pre-market trading. EF Hutton, on Friday, maintained iSpecimen with a Buy and lowered the price target from $5.5 to $4.25.
- Pioneer Power Solutions, Inc. (NASDAQ:PPSI) rose 10.2% to $3.56 in pre-market trading. Pioneer Power Solutions, last month, said Q2 EPS results were down year over year.
- Melco Resorts & Entertainment Limited (NASDAQ:MLCO) rose 9.8% to $5.82 in pre-market trading.
- Curis, Inc. (NASDAQ:CRIS) rose 8.3% to $0.7975 in pre-market trading after dropping around 7% on Friday. The FDA, last month, notified Curis to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.
- Engine Gaming and Media, Inc. (NASDAQ:GAME) rose 8.3% to $0.60 in pre-market trading after dropping around 6% on Friday.
- Galera Therapeutics, Inc. (NASDAQ:GRTX) rose 7.8% to $1.66 in pre-market trading. Galera Therapeutics, last month, posted a Q2 loss of $0.54 per share.
- Cohn Robbins Holdings Corp. (NYSE:CRHC) rose 7.3% to $9.84 in pre-market trading. Allwyn AG and Cohn Robbins Holdings have mutually agreed not to proceed with their earlier proposed business combination.
- Las Vegas Sands Corp. (NYSE:LVS) rose 6.6% to $37.80 in pre-market trading.
- PG&E Corporation (NYSE:PCG) rose 5.9% to $13.35 in pre-market trading.
Don’t forget to check out our premarket coverage here .
Losers
- Golden Sun Education Group Limited (NASDAQ:GSUN) rose 18.9% to $42.90 in pre-market trading after jumping 92% on Friday.
- Kiromic BioPharma, Inc. (NASDAQ:KRBP) shares fell 16.8% to $0.3121 in pre-market trading after jumping 46% on Friday.
- Color Star Technology Co., Ltd. (NASDAQ:CSCW) fell 14.6% to $1.51 in pre-market trading after dipping around 34% on Friday.
- Sonendo, Inc. (NYSE:SONX) fell 13.5% to $1.02 in pre-market trading. Sonendo shares jumped 30% on Friday after the company announced a $63 million private placement.
- Helius Medical Technologies, Inc. (NASDAQ:HSDT) fell 11.9% to $0.3129 in pre-market trading.
- Ucommune International Ltd (NASDAQ:UK) fell 11.3% to $2.66 in pre-market trading after tumbling over 41% on Friday.
- RVL Pharmaceuticals plc (NASDAQ:RVLP) fell 9.9% to $2.00 in pre-market trading after declining 14% on Friday.
- PagerDuty, Inc. (NYSE:PD) fell 9.4% to $20.40 in pre-market trading.
- Stabilis Solutions, Inc. (NASDAQ:SLNG) shares fell 8.6% to $6.83 in pre-market trading after declining 7% on Friday.
- Kaixin Auto Holdings (NASDAQ:KXIN) shares fell 8.5% to $0.8536 in pre-market trading after jumping 12% on Friday.
- Golden Ocean Group Limited (NASDAQ:GOGL) shares fell 7.4% to $7.67 in pre-market trading. Jefferies downgraded Golden Ocean Group from Buy to Hold and lowered the price target from $14 to $10.
- Avenue Therapeutics, Inc. (NASDAQ:ATXI) fell 6.8% to $4.19 in pre-market trading. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split.